Regeneron Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Examining Key Revenue Metrics

Biotech Revenue Battle: Regeneron vs. Celldex

__timestampCelldex Therapeutics, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201435860002819557000
Thursday, January 1, 201554800004103728000
Friday, January 1, 201667860004860427000
Sunday, January 1, 2017127430005872227000
Monday, January 1, 201895380006710800000
Tuesday, January 1, 201935730007863400000
Wednesday, January 1, 202074180008497100000
Friday, January 1, 2021465100016071700000
Saturday, January 1, 2022235700012172900000
Sunday, January 1, 2023688300013117200000
Monday, January 1, 202414202000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biotechs: Regeneron vs. Celldex

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Regeneron Pharmaceuticals, Inc. has consistently outperformed Celldex Therapeutics, Inc. in terms of revenue. From 2014 to 2023, Regeneron's revenue surged by over 360%, peaking at approximately $13.1 billion in 2023. In contrast, Celldex's revenue, while showing some growth, remained relatively modest, with a peak of around $12.7 million in 2017.

Key Insights

  • Regeneron's Dominance: By 2021, Regeneron's revenue had more than doubled from its 2014 figures, showcasing its robust market presence and successful product pipeline.
  • Celldex's Challenges: Despite a promising start, Celldex's revenue fluctuated, highlighting the challenges smaller biotech firms face in scaling operations.

This comparison underscores the importance of strategic innovation and market adaptation in the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025